Q-omics provides the consensus-scored METTL4 profile across patient tissues and cancer cell-line models. METTL4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, METTL4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, METTL4 RNA expression shows 20,690 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where METTL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL4 survival associations across molecular data types. METTL4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL4 RNA expression–survival associations across cancer types. High METTL4 expression shows unfavorable associations in MESO, LIHC, LGG, KICH and UVM, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for METTL4 RNA expression.
This table summarizes METTL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METTL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL4 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, CHOL and LUSC. The THCA box plot shows higher METTL4 RNA expression in normal versus tumor tissue (log2 FC = −0.895, t-test p < 0.001).
This table shows molecular features associated with METTL4 in patient tissues and cancer cell lines. In patient samples, METTL4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
